Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXA1125 in Fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 (PASC)
NCT05152849Phase 2Completed
- Sponsor
- Axcella
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AXA1125 in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by Axcella. Started Dec 2021; status: completed.
02
Drugs
AXA1125
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT05152849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152849.